$0.17 EPS Expected for Elanco Animal Health Incorporated (NYSE:ELAN) This Quarter

Brokerages expect Elanco Animal Health Incorporated (NYSE:ELAN) to post earnings per share (EPS) of $0.17 for the current quarter, Zacks reports. Four analysts have provided estimates for Elanco Animal Health’s earnings. The lowest EPS estimate is $0.16 and the highest is $0.19. Elanco Animal Health reported earnings of $0.12 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 41.7%. The business is expected to report its next earnings results on Wednesday, February 23rd.

On average, analysts expect that Elanco Animal Health will report full-year earnings of $1.01 per share for the current financial year, with EPS estimates ranging from $1.00 to $1.03. For the next year, analysts anticipate that the business will report earnings of $1.24 per share, with EPS estimates ranging from $1.18 to $1.30. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Elanco Animal Health.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Friday, November 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.17 by $0.02. Elanco Animal Health had a positive return on equity of 5.79% and a negative net margin of 14.56%. The company had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the prior year, the company earned $0.13 earnings per share. The firm’s revenue for the quarter was up 27.1% on a year-over-year basis.

A number of equities analysts have commented on ELAN shares. Morgan Stanley started coverage on Elanco Animal Health in a report on Thursday, November 18th. They set an “overweight” rating and a $40.00 target price for the company. Zacks Investment Research raised Elanco Animal Health from a “sell” rating to a “hold” rating in a research note on Tuesday, November 9th. Stifel Nicolaus downgraded Elanco Animal Health from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $37.00 to $34.00 in a report on Thursday, October 28th. Finally, Credit Suisse Group started coverage on shares of Elanco Animal Health in a research note on Thursday, August 5th. They issued an “outperform” rating and a $38.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Buy” and an average price target of $37.25.

ELAN traded down $1.28 during trading hours on Thursday, reaching $30.79. 3,431,800 shares of the company’s stock traded hands, compared to its average volume of 3,703,289. The company has a quick ratio of 1.30, a current ratio of 2.32 and a debt-to-equity ratio of 0.82. The firm has a 50-day moving average price of $32.59 and a 200 day moving average price of $33.65. The firm has a market capitalization of $14.57 billion, a PE ratio of -21.68, a PEG ratio of 0.64 and a beta of 0.82. Elanco Animal Health has a 52-week low of $27.33 and a 52-week high of $37.49.

In other Elanco Animal Health news, major shareholder Elanco Animal Health Inc acquired 45,508,938 shares of the company’s stock in a transaction that occurred on Friday, August 27th. The stock was purchased at an average price of $9.25 per share, for a total transaction of $420,957,676.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director R David Hoover purchased 5,000 shares of the business’s stock in a transaction on Monday, November 15th. The shares were bought at an average price of $31.79 per share, for a total transaction of $158,950.00. The disclosure for this purchase can be found here. Corporate insiders own 6.11% of the company’s stock.

Several large investors have recently made changes to their positions in ELAN. Captrust Financial Advisors acquired a new position in shares of Elanco Animal Health in the first quarter valued at approximately $28,000. Great West Life Assurance Co. Can increased its holdings in Elanco Animal Health by 9.9% in the first quarter. Great West Life Assurance Co. Can now owns 317,384 shares of the company’s stock valued at $9,287,000 after purchasing an additional 28,526 shares during the period. California State Teachers Retirement System boosted its stake in Elanco Animal Health by 0.7% during the first quarter. California State Teachers Retirement System now owns 829,954 shares of the company’s stock worth $24,442,000 after acquiring an additional 5,699 shares in the last quarter. Man Group plc lifted its stake in shares of Elanco Animal Health by 680.5% in the first quarter. Man Group plc now owns 62,262 shares of the company’s stock valued at $1,834,000 after buying an additional 54,285 shares in the last quarter. Finally, Twinbeech Capital LP boosted its holdings in Elanco Animal Health by 105.3% during the 1st quarter. Twinbeech Capital LP now owns 29,400 shares of the company’s stock worth $866,000 after acquiring an additional 15,077 shares during the last quarter. Institutional investors own 98.46% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health, Inc engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.

Further Reading: What is a Roth IRA?

Get a free copy of the Zacks research report on Elanco Animal Health (ELAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.